AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16139331
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg/day plus Warfarin (INR 2.0‐2.5)
Trial: 16139331
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (Aspirin, Warfarin, or both)
Trial: 3207127
Drug: Oral phenobarbital
RxNorm normalized name: phenobarbital Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phenobarbital (90 mg daily)
Trial: 1920342
Drug: Labetalol (100-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (100-800 mg twice daily)
Trial: 977134
Drug: Griseofulvin tablets
RxNorm normalized name: Griseofulvin Tablets
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin tablets containing dioctyl sodium sulfosuccinate, cetyl pyridinium chloride and polysorbate 80
Trial: 977134
Drug: Griseofulvin tablets
RxNorm normalized name: Griseofulvin Tablets
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin tablets only
Trial: 31965616
Drug: Detomidine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (0.03 mg/kg bwt)
Trial: 31965616
Drug: Xylazine (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine (1.1 mg/kg bwt)
Trial: 27732034
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT) + Work Therapy
Trial: 27732034
Drug: Work Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work Therapy (Control)
Trial: 23121002
Drug: Psychoeducative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducative group therapy (six sessions during pregnancy and one after childbirth)
Trial: 23121002
Drug: Psychoeducative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducative group therapy (n = 90 participants)
Trial: 23121002
Drug: Psychoeducative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducative group therapy
Trial: 15503108
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 400 mg/d titrated to 1200 mg/d, then maintained or increased to 2400 mg/d or 3600 mg/d if not beneficial
Trial: 2894070
Drug: Azo compounds
RxNorm normalized name: Azo
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azo compounds (sulphasalazine and olsalazine)
Trial: 2894070
Drug: Slow-release compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release compounds (Pentasa, Asacol, and Salofalk)
Trial: 2894070
Drug: Azo compounds
RxNorm normalized name: Azo
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azo compounds
Trial: 2894070
Drug: Slow-release compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release compounds
Trial: 28648148
Drug: Debt advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debt advice provided by the CAB, treatment as usual (TAU), and two debt advice leaflets.
Trial: 18317194
Drug: ProDisc-L lumbar
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProDisc-L lumbar disc replacement
Trial: 12706031
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy intervention program
Trial: 15321209
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of epidural bupivacaine (0.25%) at cervical dilatation <4 cm
Trial: 15321209
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of epidural bupivacaine (0.25%) at cervical dilatation >=4 cm
Trial: 31805247
Drug: Phonomotor treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonomotor treatment (56-60 hr over 6 weeks)
Trial: 31805247
Drug: Semantic Feature
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Semantic Feature Analysis (SFA) treatment (56-60 hr over 6 weeks)
Trial: 27836235
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery (using a model-predictive control algorithm to direct subcutaneous delivery of rapid-acting insulin analogue without meal-time insulin boluses)
Trial: 27836235
Drug: Conventional subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subcutaneous insulin delivery according to local clinical guidelines
Trial: 24953206
Drug: Triple boceprevir-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple boceprevir-based antiviral therapy
Trial: 19277904
Drug: IA TPA
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA TPA (22 mg over 2 h)
Trial: 17318803
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of gentamicin (antibiotic)
Trial: 11443568
Drug: Meningococcal C
RxNorm normalized name: meningococcal conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal C conjugate (MCC) vaccine after MACP vaccination
Trial: 9860404
Drug: Pentoxifylline (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1.4 mg/kg BW, n = 10 patients)
Trial: 9860404
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% solution (n = 10 patients)
Trial: 2707048
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g intravenously pre‐operatively)
Trial: 2707048
Drug: Clavulanate-potentiated amoxycillin
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clavulanate-potentiated amoxycillin (1200 mg, repeated for 2 more doses if necessary)
Trial: 883332
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for patients with histologically positive axillary nodes
Trial: 21385249
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (one-hour single music session)
Trial: 19023677
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 IV over 10 min and gemcitabine 800 mg/m2 IV at 10 mg/m2 per minute on days 1 and 15 of an every-4-weeks schedule with vitamin B12 and folate supplementation
Trial: 15017629
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with a proton pump inhibitor (PPI), amoxicillin, and clarithromycin; Omeprazole 20 mg or Lansoprazole 30 mg twice daily; Clarithromycin 200 mg 3 times daily; Amoxicillin 500 mg 3 times daily for 1 week
Trial: 9568665
Drug: Open plug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open plug and patch repair
Trial: 1774727
Drug: Patient-controlled infuser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled infuser system (2.0 mg incremental dose with a 10-minute lock-out interval)
Trial: 1774727
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injections (10-15 mg every three hours)
Trial: 6167759
Drug: Bleomycin in
RxNorm normalized name: bleomycin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin in addition to conventional four drug regimen (vincristine, adriamycin, cyclophosphamide, actinomycin D)
Trial: 30576030
Drug: Present‐Centered Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present‐Centered Therapy (PCT)
Trial: 30944103
Drug: rhNGF eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhNGF eye drops at 20 μg/mL (Group 1: G1)
Trial: 30944103
Drug: rhNGF eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhNGF eye drops at 4 μg/mL (Group 2: G2)
Trial: 26030354
Drug: Oral vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vaccination with live attenuated E. ictaluri isolate (1:100 dilution, ∼5 × 10⁶ CFU/g of feed)
Trial: 26030354
Drug: Oral vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vaccination with live attenuated E. ictaluri isolate (1:10 dilution, ∼5 × 10⁷ CFU/g of feed)
Trial: 21314226
Drug: CAD/DM Smart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAD/DM Smart Form (on-treatment analysis)
Trial: 21314226
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (on-treatment analysis)
Trial: 15973964
Drug: DHEA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (25 mg twice daily)
Trial: 15973964
Drug: DHEA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (25 mg twice daily) after exercise
Trial: 8961776
Drug: High-dose gepirone-ER
RxNorm normalized name: gepirone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gepirone-ER (20-100 mg)
Trial: 8961776
Drug: Low-dose gepirone-ER
RxNorm normalized name: gepirone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose gepirone-ER (10-50 mg)
Trial: 1383622
Drug: Ranolazine 240
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine 240 mg
Trial: 1383622
Drug: Ranolazine plasma
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine plasma levels above 500 ng/ml
Trial: 1383622
Drug: Ranolazine plasma
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine plasma levels below 500 ng/ml
Trial: 25394855
Drug: Cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (200 mg/day) plus aspirin (100 mg/day)
Trial: 25131413
Drug: Standardized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oral care protocol (twice a day including tooth brushing, tongue brushing, flossing, mouth rinse, and lip care)
Trial: 25131413
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral care practices
Trial: 25131413
Drug: Standardized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oral care protocol
Trial: 22321916
Drug: Internet-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-administered cognitive behavioural therapy (ICBT), tailored according to symptom profile.
Trial: 3069486
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg daily)
Trial: 12074359
Drug: Lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20 mg daily)
Trial: 3771812
Drug: Erythromycin (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (333 mg tid)
Trial: 30067745
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral (DAA) therapy
Trial: 24217262
Drug: Continuous ventilation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ventilation (5 ml/kg tidal volume, 5/min frequency, zero end-expiratory pressure)
Trial: 16525677
Drug: Lymphokine-activated killer
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lymphokine-activated killer (LAK) cell therapy
Trial: 16525677
Drug: Esophagectomy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esophagectomy without LAK cell therapy
Trial: 9107083
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of recombinant human erythropoietin (rhEpo) 500 U/kg/day for 30 days after transplant
Trial: 1347258
Drug: Cicloprolol (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicloprolol (oral, once a day for 2 weeks)
Trial: 31392840
Drug: Insulin tregopil
RxNorm normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin tregopil administered 10 to 20 minutes before a meal
Trial: 31392840
Drug: Insulin tregopil
RxNorm normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin tregopil with a 6-hour between-meal interval
Trial: 31392840
Drug: Insulin tregopil
RxNorm normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin tregopil 4-hour group during afternoon meal
Trial: 31392840
Drug: Insulin tregopil
RxNorm normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin tregopil
Trial: 25903783
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of adequate antimicrobial treatment
Trial: 25903783
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of adequate antimicrobial treatment
Trial: 16723783
Drug: Pilsicainide 50
RxNorm normalized name: Pilsicaïnide
DrugBank: Pilsicainide (DB12712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilsicainide 50 mg t.i.d. for 2 weeks
Trial: 8324212
Drug: Rifampicin 450
RxNorm normalized name: Rifampicin 450 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 450 mg + INH 300 mg
Trial: 8324212
Drug: Rifampicin 450
RxNorm normalized name: Rifampicin 450 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 450 mg + INH 300 mg + pyrazinamide 1500 mg
Trial: 30326632
Drug: Foxtail millet
RxNorm normalized name: Foxtail millet specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foxtail millet (50 g/day) for 12 weeks
Trial: 27638495
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (continuing on the waitlist without hand therapy intervention)
Trial: 24068456
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist treatment for 6 months
Trial: 20457959
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist treatment
Trial: 10588299
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin and mineral supplements for AMD
Trial: 10588299
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin supplements for cataract
Trial: 8912734
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 400 microg/d for 7 days
Trial: 1713753
Drug: Fresh frozen
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh frozen plasma (FFP) therapy (8 units daily for 3 days)
Trial: 6347109
Drug: Dexamethasone sodium
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone sodium phosphate (10 mg) administered intravenously
Trial: 9701719
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously
Trial: 19247842
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of IPP and VPP peptides
Trial: 19247842
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of IPP and VPP peptides
Trial: 19247842
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of IPP and VPP peptides
Trial: 11706093
Drug: beta-interferon-1a (betaINF1a)
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: beta-interferon-1a (betaINF1a) administered IM once a week at a dose of 30 microg for 24 weeks
Trial: 7619105
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Ca/d as calcium carbonate
Trial: 2908803
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of ketazolam daily for 15 days
Trial: 2908803
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of ketazolam continued for a further 15 days for responders
Trial: 30900575
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (1.25 g for 5 days)
Trial: 30900575
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline (4 g for 30 days)
Trial: 21985258
Drug: Cognitive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive group therapy (CGT)
Trial: 21985258
Drug: Focused psychodynamic
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused psychodynamic group therapy (FGT)
Trial: 11779591
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 12.5 mg/d for 6 months
Trial: 11779591
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (ethinyl estradiol 0.02 mg and desogestrel 0.15 mg) for 6 months
Trial: 2680085
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg once daily at bedtime for six weeks
Trial: 31166952
Drug: Biannual oral
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual oral azithromycin (20mg/kg for children, 1 g for adults)
Trial: 31166952
Drug: No programmatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No programmatic antibiotics (control group)
Trial: 23158886
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment for 14 days (S-14)
Trial: 23158886
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment for 10 days (S-10)
Trial: 23158886
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy for 14 days (T-14)
Trial: 11408326
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant patients
Trial: 8514613
Drug: ACT group
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT group (20 mg/m2 adriamycin i.v. on days 1 and 8, 100 mg cyclophosphamide p.o. on days 1-14, 20 mg tamoxifen p.o. daily)
Trial: 8514613
Drug: ACM group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACM group (20 mg/m2 adriamycin i.v. on days 1 and 8, 100 mg cyclophosphamide p.o. on days 1-14, 1200 mg medroxyprogesterone acetate p.o. daily)
Trial: 18491
Drug: SCH 16134
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 16134 (new benzodiazepine hypnotic)
Trial: 28359716
Drug: O-3FA ethyl
RxNorm normalized name: Ethyl o-hydroxybenzoate
DrugBank: Ethyl salicylate (DB15576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-3FA ethyl esters (750 mg/d DHA and 1860 mg/d EPA)
Trial: 22199129
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with fish oil (783 mg DHA, 162 mg EPA), bilberry extract (59 mg anthocyanidin), and lutein (17.5 mg) for 4 weeks
Trial: 15383019
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of iron(II) daily (Group A after first three donations)
Trial: 15383019
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of iron(II) daily (Group B after second three donations)
Trial: 15383019
Drug: Placebo (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (both treatment groups during placebo phase)
Trial: 11296070
Drug: Piracetam therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam therapy (80‐100 mg/kg per day)
Trial: 11296070
Drug: Piracetam therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam therapy
Trial: 8796815
Drug: Naloxone 1
RxNorm normalized name: naloxone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 1 or 4 mg